Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on December 2, 2019, for the month of December 2019. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a corporate governance notification regarding share capital and voting rights.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It solely discloses the status of issued share capital as of November 30, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The primary purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under FCA rules.
Important Facts for Investors
- Issued Share Capital: As of November 30, 2019, GSK had 5,382,827,454 Ordinary Shares of 25 pence each.
- Treasury Shares: 393,505,950 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,989,321,504.
- Regulatory Use: This figure is the official denominator for shareholders determining if they must notify the market of their interest or changes thereto under FCA rules.